These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2242517)

  • 1. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence.
    Holme I
    Circulation; 1990 Dec; 82(6):1916-24. PubMed ID: 2242517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesterol reduction in single and multifactor randomized trials: relationship to CHD incidence and total mortality as found by meta analysis of twenty-two trials.
    Holme I
    Blood Press Suppl; 1992; 4():29-34. PubMed ID: 1345332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol reduction yields clinical benefit. A new look at old data.
    Gould AL; Rossouw JE; Santanello NC; Heyse JF; Furberg CD
    Circulation; 1995 Apr; 91(8):2274-82. PubMed ID: 7697857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
    Gould AL; Davies GM; Alemao E; Yin DD; Cook JR
    Clin Ther; 2007 May; 29(5):778-794. PubMed ID: 17697899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol reduction and its impact on coronary artery disease and total mortality.
    Holme I
    Am J Cardiol; 1995 Sep; 76(9):10C-17C. PubMed ID: 7572677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of lowering serum cholesterol on coronary heart disease risk.
    Rossouw JE
    Med Clin North Am; 1994 Jan; 78(1):181-95. PubMed ID: 8283930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol lowering and the reduction of CHD incidence and total mortality: results from a meta-analysis of randomized trials.
    Holme I
    Cardiovasc Drugs Ther; 1992 Apr; 6(2):101-2. PubMed ID: 1390319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol reduction and clinical benefit. Are there limits to our expectations?
    Fager G; Wiklund O
    Arterioscler Thromb Vasc Biol; 1997 Dec; 17(12):3527-33. PubMed ID: 9437202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.
    Marchioli R; Marfisi RM; Carinci F; Tognoni G
    Arch Intern Med; 1996 Jun; 156(11):1158-72. PubMed ID: 8639010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [All mortality by cause of death. The challenge of coronary prevention].
    Fernández-Cruz A
    Rev Esp Cardiol; 1998; 51 Suppl 6():23-9. PubMed ID: 10050141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current developments in prevention of coronary heart disease].
    Windler E
    Z Arztl Fortbild (Jena); 1996 Feb; 90(1):7-10. PubMed ID: 8650967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and regression of coronary atherosclerosis. Is it safe and efficacious therapy?
    Montague T; Tsuyuki R; Burton J; Williams R; Dzavik V; Teo K
    Chest; 1994 Mar; 105(3):718-26. PubMed ID: 8131532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering cholesterol: effects on trauma death, cancer death and total mortality.
    MacMahon S
    Aust N Z J Med; 1992 Oct; 22(5 Suppl):580-2. PubMed ID: 1449443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of dietary intervention studies: effect on coronary events and on total mortality.
    Truswell AS
    Aust N Z J Med; 1994 Feb; 24(1):98-106. PubMed ID: 8002875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 1. A meta-analysis of cholesterol-lowering trials.
    Silberberg JS; Henry DA
    Med J Aust; 1991 Nov; 155(10):665-6, 669-70. PubMed ID: 1834922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projected coronary heart disease risk benefit with ezetimibe.
    Davies GM; Cook JR; Erbey J; Alemao E; Veltri EP
    Atherosclerosis; 2005 Apr; 179(2):375-8. PubMed ID: 15777556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.